<DOC>
	<DOC>NCT00903110</DOC>
	<brief_summary>The Eu-IGFD is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry. The purpose of this study is to collect long-term safety information on the use of recombinant DNA-derived human Insulin-like Growth Factor-1 (rhIGF-I) Increlex® replacement therapy for the treatment of children with growth failure.</brief_summary>
	<brief_title>European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry</brief_title>
	<detailed_description>Surveillance registry, defined as a post-authorisation observational registry, called the Eu-IGFD {European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database} which is intended primarily to monitor the safety of Increlex® replacement therapy in children with growth failure and secondly to follow the effectiveness of this treatment. Patients who have already started Increlex® therapy before entering this observational registry may be included in this registry and data will be collected retrospectively.</detailed_description>
	<criteria>All subjects beginning therapy with Increlex® or those previously treated with Increlex® by a participating qualified practitioner Parents or legally authorized representatives if applicable must give signed informed consent before any registryrelated activities are conducted. Assent from the subject should also be obtained as appropriate Subject currently participating in an Increlex® clinical trial Subject currently participating in any clinical trial for growth retardation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>